ORLANDO, Florida — Another phase 3 trial has shown efficacy for idelalisib (Zydelig, Gilead Sciences, Inc) in relapsed or refractory chronic lymphocytic leukemia (CLL). The novel drug was approved ...
June 3, 2012 (Chicago, Illinois) — New long-term results from a German trial of patients with indolent and slow-growing lymphoma confirm that a simpler 2-drug combination can be used in these patients ...
Calquence's approval with bendamustine and Rituxan offers a new first-line treatment for MCL patients ineligible for HSCT, marking a significant therapeutic advancement. Clinical trials showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results